Skip to main content
. Author manuscript; available in PMC: 2014 Sep 15.
Published in final edited form as: Cochrane Database Syst Rev. 2011 Jun 15;(6):CD004718. doi: 10.1002/14651858.CD004718.pub3

Comparison 11.

PHASE-SPECIFIC TREATMENT (E-EPA) + ATYPICALS vs PLACEBO + ATYPICALS

Outcome or subgroup title No. of studies No. of participants Statistical method Effect size
1 Leaving the study early by 12 weeks 1 80 Risk Ratio (M-H, Fixed, 95% CI) 0.83 [0.28, 2.51]
2 Global state: Not responded to treatment by 12 weeks 1 80 Risk Ratio (M-H, Fixed, 95% CI) 0.9 [0.57, 1.43]